• Andrew Charles, Charles Flippen, Marcela Romero Reyes, and Kevin C Brennan.
• Headache Research and Treatment Program, Department of Neurology, David Geffen School of Medicine at UCLA, 635 Charles Young Drive, Suite 575, Los Angeles, CA 90095, USA. acharles@ucla.edu
• J Headache Pain. 2007 Sep 1; 8 (4): 248250248-50.

AbstractThe objective was to retrospectively characterise the efficacy of memantine as preventive therapy in a series of patients with frequent migraine. Patients in a university headache clinic completed a survey regarding their experience with memantine, and medical records were reviewed. All patients who received memantine as preventive therapy for migraine over a 15-month period were mailed surveys and consent forms for record review. Patients were treated with memantine beginning at a dose of 5 mg/day, increasing if needed by 5 mg/week up to 10 mg twice a day. The majority of patients (36 out of 54) treated with memantine for at least 2 months reported a significant reduction in estimated headache frequency, and improved function. Side effects were uncommon and generally mild. This limited retrospective case review suggests that memantine may be an effective preventive therapy for patients with frequent migraine. A prospective trial is warranted.

22 keywords...

hide…